Anti-ErbB2 antibodies

Abstract

Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.

1 - 41 . (canceled)  
     
     
         42 . A composition comprising a first isolated antibody that binds Domain 1 (SEQ ID NO: 1) of ErbB2 and thereby induces cell death in cells overexpressing ErbB2.  
     
     
         43 . The composition of  claim 42 , wherein said antibody binds epitope 7C2/7F3 (SEQ ID NO: 2) of ErbB2.  
     
     
         44 . The composition of  claim 42 , wherein said antibody comprising CDRs of antibody 7C2 or 7F3.  
     
     
         45 . The composition of  claim 42 , wherein said antibody induces apoptosis in said cells.  
     
     
         46 . The composition of  claim 42 , further comprising an isolated second antibody that binds ErbB2 at a different domain than Domain 1 and inhibits growth of cells overexpressing ErbB2.  
     
     
         47 . The composition of  claim 46 , wherein said first antibody comprises CDRs of antibody 7C2 or 7F3.  
     
     
         48 . The composition of  claim 46 , wherein said second antibody comprises CDRs of antibody 4D5.  
     
     
         49 . The composition of  claim 46 , wherein said first antibody comprises CDRs of antibody 7C2 or 7F3 and said second antibody comprises CDRs of antibody 4D5.  
     
     
         50 . An isolated nucleic acid sequence encoding antibody that binds Domain 1 (SEQ ID NO: 1) of ErbB2 and thereby induces cell death in cells overexpressing ErbB2.  
     
     
         51 . The nucleic acid sequence of  claim 50 , encoding an antibody that binds epitope 7C2/7F3 (SEQ ID NO: 2) of ErbB2.  
     
     
         52 . The nucleic acid sequence of  claim 50 , encoding an antibody comprising CDRs of antibody 7C2 or 7F3.  
     
     
         53 . The nucleic acid sequence of  claim 52 , further composing a nucleic acid sequence encoding a second antibody comprising CDRs of antibody 4D5.  
     
     
         54 . A host cell comprising a nucleic acid sequence encoding an antibody comprising CDRs of antibody 7C2 or 7F3.  
     
     
         55 . The host cell of  claim 54 , further comprising a nucleic acid sequence encoding a second antibody comprising CDRs of antibody 4D5.  
     
     
         56 . The host cell of  claim 54 , wherein the host cell is a hybridoma cell line.  
     
     
         57 . A kit comprising an antibody that binds Domain 1 (SEQ ID NO: 1) of ErbB2 and thereby induces cell death in cells overexpressing ErbB2 and a second antibody that binds ErbB2 at a different domain than Domain 1 and inhibits growth of cells overexpressing ErbB2, adapted for simultaneous or sequential administration.  
     
     
         58 . A method for inducing cell death in cell that overexpresses ErbB2, comprising exposing a cell that overexpresses ErbB2 to an isolated antibody that binds Domain 1 (SEQ ID NO: 1) of ErbB2, thereby inducing apoptosis in said cells.  
     
     
         59 . The method of  claim 58 , wherein said antibody binds epitope 7C2/7F3 (SEQ ID NO: 2) of ErbB2.  
     
     
         60 . The method of  claim 58 , wherein said antibody comprises CDRs of antibody 7C2 or 7F3.  
     
     
         61 . The method of  claim 58 , further comprising exposing said cell to radiation.  
     
     
         62 . The method of  claim 58 , further comprising exposing said cell to a chemotherapeutic agent.  
     
     
         63 . The method of  claim 58 , further comprising exposing said cell to a second antibody that binds ErbB2 at a different domain than Domain 1 and inhibits growth of cells overexpressing ErbB2.  
     
     
         64 . The method of  claim 63 , wherein said second antibody comprises CDRs of antibody 4D5.  
     
     
         65 . The method of  claim 63 , wherein said first antibody comprises CDRs of antibody 7C2 or 7F3 and said second antibody comprises CDRs of antibody 4D5.  
     
     
         66 . The method of  claim 63 , wherein said cell is exposed to said antibody that binds Domain 1 prior to exposure of the cell to said second antibody.